On Friday, Minnesota Rep. Ilhan Omar (D-Minn.) will introduce a potentially groundbreaking piece of federal legislation in the House of Representatives—one allocating $10 billion in funding to fight Long Covid, the increasingly widespread, chronic condition that follows many Covid infections. The Long Covid Research Moonshot Act is a companion bill to one that Sen. Bernie Sanders (I-Vt.) introduced in the Senate in August.
“Long Covid is a silent health crisis impacting over twenty-three million Americans, including one million children,” Omar said in a statement to Mother Jones. (Rep. Ayanna Pressley, D-Mass., is the co-lead on the legislation.) “I’m proud to lead this effort in the House to recognize Long Covid as the public health emergency that it is and invest in countering the effects of this terrible disease.”
“Long Covid is a silent health crisis impacting over twenty-three million Americans, including one million children,” Rep. Omar said.
Long Covid symptoms often include debilitating fatigue, and many people found to have it have also been diagnosed with conditions like myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome. ME/CFS, which is characterized by post-exertional malaise, is known to be associated with other infectious diseases—the CDC states that about 1 in 10 people infected by the Epstein-Barr virus (which 95 percent of adults get) experience ME/CFS-like symptoms. And research shows that repeated Covid infections increase people’s risk of developing Long Covid.
The Long Covid Research Moonshot Act would establish a new research program within the National Institutes of Health to better understand the condition (and others, like ME/CFS and POTS) with its own database, advisory board, and a new grant process to accelerate clinical trials. It would fund public health education and comprehensive care clinics dedicated to Long Covid, especially in underserved, disproportionately affected communities—and would require any new treatments developed through the act to be reasonably priced and accessible to more patients.
“We know that the only path forward out of this generational crisis is to fund research that builds on our expertise about infection-associated chronic conditions like ME/CFS, and that is accountable to the patient community for delivering results, including clinical trials,” said Laurie Jones, executive director of patient advocacy group #MEAction. “The Long Covid Research Moonshot Act lays out a comprehensive plan for doing just that.”
Megan Carmilani, the president of Long Covid Families, believes the bill would fund vital research into how Long Covid presents in young people, a focus of her organization, and called on Congress “to prioritize the health and wellbeing of our nation’s children by supporting this bill as well.”
The Long Covid Research Moonshot Act is not Congress’ first attempt to fund such treatment. In December 2020, Congress allocated $1 billion to NIH to study the long-term impacts of Covid, and boosted that funding by more than $500 million this year.
But a 2022 attempt, Pressley’s TREAT Long Covid Act, did not make it out of committee—despite having 41 co-sponsors, including Rep. Omar. That act, also unsuccessfully reintroduced in 2023, would have made direct grants to clinics that treat Long Covid and associated conditions.
Communities of color and disabled people have been disproportionately harmed by Long Covid. Black and Latino people, for instance, are more likely to develop Long Covid symptoms than white people. Disabled people are twice as likely to do so as non-disabled people. A February 2023 analysis published by JAMA Network found that people with Long Covid symptoms, which can include severe fatigue and issues with cognitive function, are more likely to be unemployed. The only way not to get Long Covid is to avoid Covid infections, underscoring the importance of mask-wearing and high-quality air filtration.
“We must take bold action to help Americans suffering from Long Covid,” Omar said in her statement.
Enlarge / An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (credit: Getty | helby Knowles)
Pharmaceutical giant Eli Lilly earned praise this week with an announcement that it is now selling starter dosages of its popular weight-loss drug tirzepatide (Zepbound) at a price significantly lower than before. But the cheers were short-lived as critics quickly noticed that Lilly also quietly raised the price on current versions of the drug—a move that was notably missing from the company's press release this week.
In the past, Lilly sold Zepbound only in injectable pens with a list price of $1,060 for a month's supply. Several dosages are available—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg—and patients progressively increase their dosage until they reach a maintenance dosage. The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg. The higher the dose, the more the weight loss. For instance, people using the 15 mg doses lost an average of 21 percent of their weight over 17 months in a clinical trial, while those on 5 mg doses only lost an average of 15 percent of their weight.
On Tuesday, Lilly announced that it will now sell Zepbound in vials, too. And a month's supply of vials with the 2.5 mg doses will cost $399, while a month's supply of 5 mg doses is priced at $549—a welcome drop from the $1,060 price tag. These prices are for a self-pay option, meaning that patients with a valid, on-label prescription can buy them directly from Lilly if they have no insurance or have insurance that does not cover the drug.
Enlarge / Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company's headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023. (credit: Getty | Carsten Snejbjerg)
After some persuasion from Sen. Bernie Sanders (I-Vt.), the CEO of Novo Nordisk will testify before lawmakers later this year on the "outrageously high cost" of the company's diabetes and weight-loss drugs—Ozempic and Wegovy—in the US.
CEO Lars Jørgensen will appear before the Senate Committee on Health, Education, Labor, and Pensions (HELP), which is chaired by Sanders, in early September. The agreement came after a conversation with Sanders in which the CEO reportedly "reconsidered his position" and agreed to testify voluntarily. As such, Sanders has canceled a vote scheduled for June 18 on whether to subpoena Novo Nordisk to discuss its US prices, which are considerably higher than those of other countries.
The independent lawmaker has been working for months to pressure Novo Nordisk into lowering its prices and appearing before the committee. In April, Sanders sent Jørgensen a letter announcing an investigation into the prices and included a lengthy set of information requests. In May, the committee's investigation released a report suggesting that Novo Nordisk's current pricing threatens to "bankrupt our entire health care system."
Login
